SYBLEU, Inc. intends to engage in the development of regenerative medical applications. After conducting successful Phase I or Phase II clinical trials, it would either attempt to sell or license those developed applications or advance the application further to Phase III clinical trials. The company was founded on June 12, 2020 and is headquartered in Bronx, NY.